iMOST is a rapid, mobile phone-based health test platform that can be used in personal, point-of-care and clinical settings. Credit: Essenlix.

Digital health start-up Essenlix has collaborated with Roche Diagnostics Norway to deploy its instant Mobile Self Test (iMOST) platform to increase patient at-home testing.

Essenlix was selected by Roche as its partner for this initiative after a long association, the company said. Roche will now deploy Essenlix’s iMOST as the platform for its patient-at-home-test solution in the country.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A rapid, portable, mobile phone-connected health test platform, iMOST can be used in personal, point-of-care and clinical settings.

Users can carry out a precise diagnostic health test on themselves, irrespective of the place or time, with one drop of body fluid and a smartphone. The affordable test delivers results within 60 seconds, which will be shared with medical specialists instantly.

Compared to standard instruments and devices, iMOST is different in various aspects.

iMOST is ‘intelligent fault tolerant’ and offers reliable lab-quality test results with the help of a simple device even when sample, device, process and operation are not in ideal conditions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The ‘all-in-one’ platform utilises a single instrument/device to conduct the test for almost all sample types, including blood, saliva, urine, swaps, sputum, breath, mucus and tissues; as well as for most assay types. It does not require separate specimen holders and instruments.

Essenlix co-founder and chairman Dr Stephen Chou said: “This partnership is an excellent vehicle to further demonstrate and test the capabilities of Essenlix iMOST platform for personal, point-of-care and clinical use in Norway.

“It is also an important step forward to make the iMOST platform a solution to the unmet need of instant personal health testing, providing a key missing link between personal health, remote monitoring and treatment, and e-health services in Norway.”

Essenlix is equipped to produce more than ten million iMOST test cards a year using its manufacturing lines.

Last week, the US Food and Drug Administration granted emergency use authorisation to Roche’s cobas SARS-CoV-2 Test for asymptomatic people and those with suspected Covid-19.